Within this group of lower tumor stages, IDO-positive patients reached a calculated average OS of 142.1 months (median not reached, average 95% CI 115.2-168.9 months) compared to an average OS of 37.1 months (95% CI 23.6-50.7 months, median OS 30.5 months (95% CI 19.9-41.1 months, p < 0.001)) (Figure 4(c)). Here, IDO1 is linked to neoplasm.